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ABSTRACT
Background: Vulvar cancer treatment is mostly curative, but also has high 
morbidity rates. In a search for markers that can identify patients at risk of metastases, 
we investigated the prognostic value of L1-cell adhesion molecule (L1CAM) in large 
series of vulvar squamous cell carcinomas (VSCCs). L1CAM promotes cell motility and 
is an emerging prognostic factor for metastasis in many cancer subtypes.
Results: L1CAM expression was observed at the invasive front or in spray-
patterned parts of 17% of the tumours. L1CAM-positive tumours expressed vimentin 
more often, but L1CAM expression was not associated with TP53 or CTNNB1 
mutations. Five-year survival was worse for patients with L1CAM expression (overall 
survival 46.1% vs 63.6%, P=.014, disease specific survival 63.8% vs 80.0%, P=.018). 
Multivariate analysis indicates L1CAM expression as an independent prognostic 
marker (HR 2.9, 95% CI 1.10–7.68). An in vitro spheroid invasion assay showed 
decreased invasion of L1CAM-expressing VSCC spindle cells after treatment with 
L1CAM-neutralising antibodies.
Materials and Methods: Paraffin-embedded tumour tissue from two cohorts 
(N=103 and 245) of primary VSCCs were stained for L1CAM, vimentin and E-cadherin. 
Patients of the first cohort were tested for human papilloma virus infection and 
sequenced for TP53 and CTNNB1 (β-catenin) mutations. The expression of L1CAM 
was correlated to clinical characteristics and patient survival.
Conclusion: This is the first study to show high L1CAM-expression at the 
infiltrating margin of VSCC’s. L1CAM-expressing VSCCs had a significantly worse 
prognosis compared to L1CAM-negative tumours. The highest expression was 
observed in spindle-shaped cells, where it might be correlated to their invasive 
capacity.
INTRODUCTION
Vulvar cancer is the fourth most common 
gynaecological malignancy affecting approximately 2 
in 100.000 women each year in developed countries 
[1, 2]. Vulvar cancer typically occurs in postmenopausal 
women: the mean age of diagnosis is 70 years [3, 4]. Two 
subgroups of vulvar squamous cell carcinoma (VSCC) 
are currently recognised. The first generally affects 
younger patients and is associated with infection by the 
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human papilloma virus (HPV). The second develops 
independently from HPV infection and is associated with 
mutations in the TP53 gene [5].
Patients diagnosed with vulvar cancer at an early 
stage generally have a good prognosis (90% 5-year 
survival for FIGO stage 1 patients) [3]. However, some 
patients suffer from rapidly progressing tumours that 
often recur and metastasize. Surgical treatment of 
early stage vulvar cancer is curative in most cases, but 
unfortunately, it also results in high morbidity rates [6, 7]. 
Researchers have tried to find prognostic markers that can 
differentiate patients who require aggressive (surgical) 
treatment from patients who would benefit from a more 
conservative and less invasive approach. This can include 
less radical surgical margins or to waive lymph node 
dissection or sentinel node procedure [8]. Despite these 
efforts, no prognostic markers are currently used in the 
clinical management of VSCC patients, except for lymph 
node metastasis, which is currently considered the most 
accurate predictor for prognosis [8, 9].
L1 cell adhesion molecule (L1CAM, or CD171) 
is thought to be one of the many factors involved in 
the induction of Epithelial-to-Mesenchymal Transition 
(EMT), responsible for the gain of invasive properties of 
cancer cells. L1CAM is a membrane glycoprotein that 
plays a crucial role in neural development where it has a 
dual mechanism: it can either stimulate cell adhesion, or it 
can promote cell motility. In normal adult tissue, L1CAM 
is only expressed by nerve tissue, leukocytes and renal 
tubules of the kidney, whereas in cancer it has also been 
reported to be expressed on tumour cell surface [10–12]. 
In tumour cells, L1CAM can switch from a cell adhesion 
to a cell motility promoting role, which is demonstrated by 
its stimulating effect on invasive growth of tumour cells 
[12, 13]. This is also illustrated by studies showing high 
L1CAM expression (sometimes even exclusively), at the 
invasive border of tumours [13, 14]. Finally, L1CAM can 
induce a more invasive phenotype in cell lines [15].
The prognostic significance of L1CAM expression 
has been addressed in many different types of cancer, 
including gynaecological cancers [14, 16–23]. Recently, 
two large studies showed the prognostic significance 
of L1CAM in low grade endometrioid endometrial 
cancers [24, 25]. L1CAM was found to be expressed 
in invasive areas of epithelial ovarian cancer and was 
correlated with poor clinical outcome and unfavourable 
clinicopathological features of the disease [21].
There are several hypotheses regarding the 
underlying mechanism of L1CAM upregulation in cancer. 
The three dominant hypotheses are that L1CAM is 
upregulated by mutant p53 [26], through Wnt-signalling 
[14, 26] or through the induction of TGF-β family 
members [26, 27]. L1CAM expression has not been 
examined in vulvar cancer before, but some studies have 
reported a relation between morphological features of 
EMT and a worse survival in vulvar cancer [28, 29].
In this study, we investigated the expression of 
L1CAM in a large series of 348 VSCC patients from 
two different academic hospitals and correlated it with 
survival. In order to further understand the process of 
L1CAM upregulation, clinicopathological characteristics 
and markers for EMT were studied in one of the cohorts. 
Finally, in a pilot in vitro study we have examined the role 
of L1CAM in invasion of vulvar cancer cells.
RESULTS
From the Leiden cohort, 103 patients were included, 
and tumour sections from all patients were analysed for 
L1CAM. The average age at diagnosis was 71 years and 
the mean follow-up time was 4 years. Table 1 lists the 
characteristics of all included patients for the study cohort.
Of the 103 patients in the study cohort, 16 (16%) 
were positive for L1CAM (Table 2). Figure 1 shows an 
example of an L1CAM positive tumour. All moderate to 
strong expressing cells were found at the invasive border 
of the tumours or areas with pronounced spindle-cell 
morphology (Figure 1). None of the more differentiated 
or solid, keratinizing tumours showed any L1CAM 
positivity. HPV was detected in 17 out of the total 103 
patients (17%) and TP53 mutations in 56 patients (54%). 
Previous research from our group has shown that VSCC 
with spindle cell morphology were more likely to carry 
TP53 mutations and that spindle cell morphology was 
exclusively found in HPV negative patients [29]. Although 
L1CAM expression was more frequently seen in spindle 
patterned tumours, there was no relation between L1CAM 
upregulation and TP53 mutations and/or HPV infection. 
No CTNNB1 mutations or aberrant nuclear β-catenin 
expression were detected in any of the samples. L1CAM 
upregulation was not associated with changes in e-cadherin 
expression, since all tumours express e-cadherin. Vimentin 
expression in the tumour was detected in 29 samples 
(28.2%) and was correlated to L1CAM expression 
(Spearman’s rho 0.349, P=0.001) (Table 3). An example 
of vimentin and L1CAM expression at the invasive border 
of a tumour is shown in Supplementary Figure S3.
Comparison of survival data
Clinical data from the Leiden cohort were compared 
for patients with and without L1CAM positive tumours and 
listed in Table 2. Patients with L1CAM positive tumours 
presented more often at the highest FIGO stage (31.1% vs 
6.9%, P=.023) and if they had lymph node metastasis, it 
was more likely to be bilateral (31.3% vs 8.0%, P=.029) 
and with extracapsular growth (37.5% vs 12.6%, P=.024). 
Patients without L1CAM staining were more likely to reach 
complete remission (81.6% vs 56.2%, P=.045). L1CAM 
positive patients had a worse 5-year overall and disease 
specific survival (18.8% vs 58.7%, log rank P=.001 and 
42.8% vs 79.3%, log rank P=.013, respectively) (Figure 2).
Oncotarget26194www.impactjournals.com/oncotarget
Patients with L1CAM-expressing tumours had a 2.9 
times higher risk of dying from their cancer than patients 
lacking L1CAM expression (HR 2.9, 95% CI 1.10 – 7.68) 
when corrected for the possible confounders lymph node 
metastasis, tumour size and TP53 mutations. Also for 
overall survival, L1CAM remained to be an independent 
prognostic factor when corrected for these confounders 
(HR 2.28, 95% CI 1.13 – 4.57) (Table 4).
Validating prognostic data in an independent 
cohort
Of the 245 patients in the independent TMA cohort, 
the average age at diagnosis was 72 years and the mean 
follow-up time was 5 years. Table 5 lists the characteristics 
of all included patients in the TMA cohort.
Of these 245 patients, 44 (18%) overexpressed 
L1CAM (Table 6). The five year overall and disease 
specific survival was worse for patients with L1CAM 
expression, but it did not reach statistical significance 
(49.4% vs 61.3%, log rank P=0.074 and 70% vs 80%, log 
rank P= 0.159) (Table 6). Since no material was available 
for mutation and HPV analysis, Cox regression analysis 
was performed correcting for lymph node metastasis and 
tumour size only. Patients with L1CAM positive tumours 
showed a trend towards increased risk of dying, with a 
hazard ratio of 1.58 (95% CI 0.79 – 3.19) for disease 
specific survival and 1.48 (95% CI 0.93 – 2.35) for overall 
survival, these hazard ratios however did not reach 
statistical significance (Supplementary Table S1).
When taking all survival data together, thus creating 
a combined cohort of 348 patients (Supplementary 
Table S2) of which 60 (17%) were positive for L1CAM 
(Table 7). The 5 year overall and disease specific survival 
was significantly worse for patients with L1CAM positive 
tumours (46.1% vs 63.6%, log rank P=.014 and 63.8% vs 
80.0%, log rank P=.018) (Table 7). Patients with L1CAM 
positive tumours were more likely to have lymph node 
metastasis than patients without L1CAM expression 
(48.3% vs 35.4%, P=.048) (Table 7).
The multivariate Cox regression analysis for both 
cohorts combined, correcting for lymph node metastasis 
Table 1: Patients characteristics of the leiden cohort (n=103)
Characteristic Value
Follow up – mo (SD) 48.7 (36.1)
Age at diagnosis – year (SD) 70.7 (13.6)
Duration of symptoms – mo (IQR) 5.0 (2.0-17.3)
FIGO stage – n (%)
 Stage 1 27 (26)
 Stage 2 36 (35)
 Stage 3 29 (28)
 Stage 4 11 (11)
Lymph node metastases – n (%) 39 (38)
 Extracapsular growth – n (%) 17 (17)
Tumor size – mm (SD) 31.8 (21.7)
Infiltration depth – mm (IQR) 6.0 (4.0-10.0)
Positive resection margins – n (%) 21 (20.4)
Disease status – n (%)
 Complete remission 80 (78)
 Local recurrence 20 (19)
 Regional recurrence 9 (9)
 Died 56 (54)
 Disease specific death 25 (24)
5-yr overall survival – % (SD) 52.5 (5.1)
5-yr disease specific survival – % (SD) 74.7 (4.5)
5-yr disease free survival – % (SD) 30.0 (5.0)
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and tumour size provided a hazard ratio of 1.58 (95% CI 
1.08 – 2.32) for overall survival and 1.70 (95% CI 0.97 – 
2.97) for disease specific survival (Table 8).
L1CAM inhibition decreases invasion of VSCC 
spindle shaped but not cobble shaped cells
To analyse the potential role for L1CAM in tumour 
cell invasion, we isolated spindle- and cobble-shaped 
cells from one VSCC which contained both components. 
Epithelial origin of the spindle- and cobble cells was 
confirmed by positive immunohistochemical stainings for 
pan-cytokeratin and presence of identical TP53 mutations 
detected in the tumour from which the cells were derived. 
L1CAM expression was analysed by western blot. Figure 
3A shows that spindle shaped cells highly express L1CAM, 
whereas L1CAM expression on cobble shaped cells is very 
low. Next, both cell types were grown as spheroids and 
embedded in collagen type-I matrix to study the invasive 
properties (Figure 3B). In the presence of an L1CAM 
neutralising antibody the invasion of the spindle cell 
population can be strongly inhibited, while the invasion of 
the non-L1CAM expressing cobble shaped cells is hardly 
affected (Figure 3C and 3D). This experiment stresses 
the importance of L1CAM for the invasive potential of 
the spindle cells and opens possibilities to explore these 
antibodies in a therapeutic setting.
DISCUSSION
L1CAM expression has shown to be a marker for 
poor disease outcome in several types of cancer [14, 16–
23] and this is study is the first to evaluate the prognostic 
capacity in vulvar cancer. Taking both the Leiden and 
the TMA cohort together, L1CAM was upregulated in 
60 (17%) of all included VSCC. Patients with L1CAM 
Table 2: Comparison of patient characteristics for L1CAM positive and negative tumours in the leiden cohort
Outcome L1CAM positive L1CAM negative p-value
n=16 (16%) n=87 (84%)
Follow up – mo (SD) 29.0 (34.5) 52.3 (35.4) 0.017*
Age at diagnosis – yr (SD) 70.5 (13.1) 70.8 (13.8) 0.939
Duration of symptoms – mo (IQR) 4.0 (2.3 - 73.5) 5.0 (2.0 - 14.8) 0.573
FIGO stage – n (%) 0.023*
 stage 1 2 (13) 25 (29) 0.227
 stage 2 6 (38) 30 (35) 0.784
 stage 3 3 (19) 26 (30) 0.547
 stage 4 5 (31) 6 (7) 0.013*
Lymph node metastases – n (%) 8 (50) 31 (36) 0.401
 Extracapsular growth 6 (38) 11 (13) 0.024*
Tumor size – mm (SD) 39.5 (19.2) 30.6 (21.9) 0.156
Infiltration depth – mm (IQR) 8.0 (5.5 - 13.3) 6.0 (3.5 - 9.0) 0.145
Positive resection margins – n (%) 7 (43.8) 14 (16.1) 0.019*
Disease status – n (%)
 Complete remission 9 (56) 71 (82) 0.045*
 Local recurrence 2 (13) 18 (21) 0.771
 Regional recurrence 0 (0) 9 (10)
 Died 13 (81) 43 (49) 0.027*
 Disease specific death 7 (64) 18 (24) 0.012*
5-yr Overall survival – % (SD) 18.8 (10) 58.7 (6) 0.001*
5-yr Disease specific survival – % (SD) 42.8 (15) 79.3 (5) 0.013*
5-yr Disease free survival – % (SD) 30.0 (15) 41.6 (7) 0.266
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expressing tumours have a significantly worse 5 year 
disease specific survival compared to patients with 
normal L1CAM expression (80% vs 64%). Furthermore 
our pilot in vitro data show an important role specifically 
for L1CAM in the invasive properties of spindle shaped 
vulvar cancer cells.
There are three hypotheses how L1CAM is 
upregulated in cancer. Studies in colorectal cancer cell 
lines have shown that β-catenin (CTNNB1) mutations, and 
the subsequent aberrant activation of the Wnt signalling 
pathway, result in upregulation of L1CAM [14]. Despite 
these findings in colorectal cancer, our work and that of 
others on vulvar cancers shows no evidence of CTNNB1 
gene mutations, nor nuclear β-catenin expression [28, 33]. 
Therefore, we do not expect that Wnt-signalling through 
β-catenin is a major factor in the upregulation of L1CAM 
in vulvar cancer.
P53 has also been postulated as a regulator of L1CAM 
expression and TP53 is frequently mutated in vulvar cancer 
[26]. In our current study, there was no correlation between 
TP53 mutations and L1CAM positivity. Since HPV infection 
can alter the function of wild type p53, a relation between 
L1CAM expression and p53 aberration by either HPV 
infection or TP53 mutation was investigated, but we did 
not find any correlation. We therefore concluded that p53 
might not be driving L1CAM expression in vulvar cancer. 
A third alternative is that L1CAM expression is upregulated 
in the process of EMT [41, 42]. EMT-like changes have been 
described in vulvar cancer by us [29] and others [28] and was 
associated with poor clinical outcome. Our current findings 
show that L1CAM expression is exclusively found in areas 
with EMT-like growth (at the invasive border), or in tumours 
with predominant spray patterned growth, suggesting an 
association between EMT and L1CAM. Moreover, we 
confirmed that spindle shaped epithelial tumour cells highly 
express L1CAM protein, in contrast to their cobble shaped 
counterparts, which show very low or absent L1CAM.
Together, our findings indicate that L1CAM 
upregulation may be a consequence of EMT-like changes 
in vulvar cancer. Our spheroid invasion assay suggests 
that the invasion of these spindle shaped vulvar tumour 
cells can be strongly inhibited by treatment with L1CAM 
neutralising antibodies. These findings are in line with other 
tumour models, where treatment with L1CAM neutralising 
antibodies seems to inhibit tumour growth and metastasis 
[37]. Therefore our work contributes to the growing 
Figure 1: L1CAM expression. Two vulvar squamous cell carcinomas with spindle cell morphology (A and B) and solid growth pattern 
(C and D) stained for keratin (A and C) and L1CAM (B and D). Arrowhead: nerve axon as an internal positive control.
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evidence showing efficacy of inhibiting tumour growth 
by L1CAM antibodies and stresses the need for further 
evaluating its therapeutic potential in vulvar and other 
cancers.
The strength of this study is the relatively large 
number of included patients with vulvar cancer. When 
combining the two cohorts, the statistical power of 
our analyses increases, which underlines the potential 
prognostic value of L1CAM expression in vulvar cancer. 
We do want to encourage other institutes to reproduce our 
study in order to validate our hypothesis. Because of the 
low incidence of vulvar cancer, we suggest these should be 
multicentre studies containing at least hundreds of patients.
A potential weakness of this study is its 
retrospective design. Since therapies change and 
improve over time, using samples dating back to 1984 
might distort the survival analysis. Also, by excluding 
patients who underwent small excision biopsies 
and needed no further surgical excision, small sized 
tumours that have a relatively good prognosis might 
have been excluded. On the other hand, patients that 
did not receive surgical treatment were also excluded 
because of the large size or metastasis of their tumour. 
By including tumour size in the multivariate analysis, 
we have corrected for this possible bias. For the 
TMA cohort, only tissue micro arrays were available. 
Table 3: Correlating molecular markers to L1CAM upregulation in the leiden cohort
Outcome L1CAM positive L1CAM negative χ2 p-value Spearman 
correlation
p-value
n=16 (16%) n=87 (84%)
HPV positive – n (%) 1 (12) 16 (18) 0.462 -0.118 0.233
TP53 mutation – n (%) 10 (63) 46 (53) 0.278 0.070 0.482
HPV and/or TP53 – n (%) 11 (69) 59 (68) 0.595 0.007 0.942
Vimentin – n (%) 10 (67) 17 (24) 0.004 0.349 0.001*
Figure 2: Survival curves. Kaplan meier survival curves for the leiden cohort, n=103 A, B. and both cohorts combined, n=348 C, D. 
P-values for log-rank test.
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Table 4: Multivariate cox regression analysis for the leiden cohort (n=103)
Disease specific survival
Variable HR 95% CI
Lymph node metastasis 5.58 2.29 - 13.62
Tumour size (mm) 1.02 1.00 - 1.04
TP53 mutation 2.48 0.98 - 6.24
L1CAM staining 2.91 1.10 - 7.68
Overall survival
variable HR 95% CI
Lymph node metastasis 3.33 1.91 - 5.78
Tumour size (mm) 1.03 1.02 - 1.04
TP53 mutation 1.50 0.84 - 2.67
L1CAM staining 2.28 1.13 - 4.57
Table 5: Patients characteristics of the TMA cohort (n=245)
Characteristic n=245 Value
Follow up – mo (SD) 60.0 (50.5)
Age at diagnosis – year (SD) 71.7 (13.1)
FIGO stage – n (%)
 Stage 1 51 (21)
 Stage 2 94 (38)
 Stage 3 67 (27)
 Stage 4 33 (13)
Lymph node metastases – n (%) 92 (43)
 Extracapsular growth – n (%) 40 (16)
Tumor size – mm (SD) 33.0 (17.2)
Infiltration depth – mm (IQR) 7.0 (3.8-10.0)
Positive resection margins – n (%) 21 (8.6)
Disease status – n (%)
 Complete remission 154 (63)
 Local recurrence 50 (20)
 Regional recurrence 14 (6)
 Distant recurrence 6 (2)
 Died 120 (49)
 Disease specific death 50 (20)
5-yr Overall survival – % (SD) 59.6 (3.0)
5-yr Disease specific survival – % (SD) 78.2 (2.6)
5-yr Disease free survival – % (SD) 64.5 (3.0)
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Table 6: Comparison of patient characteristics for L1CAM positive and negative tumours in the TMA cohort
Characteristic L1CAM positive L1CAM negative p-value
n=44 (18%) n=201 (82%)
Follow up – mo (SD) 55.2 (50.2) 61.9 (50.9) 0.432
Age at diagnosis – yr (SD) 73.1 (13.0) 71.2 (13.0) 0.381
FIGO stage – n (%) 0.031*
 stage 1 7 (16) 44 (22)
 stage 2 13 (30) 81 (40
 stage 3 20 (46) 47 (23)
 stage 4 4 (9) 29 (14)
Lymph node metastases – n (%) 21 (48) 71 (35) 0.104
 Extracapsular growth 9 (21) 31 (15) 0.219
Tumor size – mm (SD) 35.8 (22.4) 32.8 (16.3) 0.303
Infiltration depth – mm (IQR) 7.0 (4.0-10.0) 7.0 (3.5-10.2) 0.912
Lymfangio invasion – n (%) 11 (25) 28 (14) 0.112
Positive resection margins – n (%) 5 (11) 16 (8) 0.386
Disease status – n (%)
 Complete remission 22 (50) 132 (66) 0.059
 Local recurrence 9 (21) 36 (18) 0.413
 Regional recurrence 2 (5) 10 (5)
 Distant recurrence 3 (7) 3 (1)
 Died 27 (61) 93 (46) 0.095
 Disease specific death 12 (27) 38 (19) 0.219
5-yr Overall survival – % (SD) 49.4 (8.2) 61.3 (3.7) 0.074
5-yr Disease specific survival – % (SD) 70.4 (8.2) 80.3 (3.0) 0.159
5-yr Disease free survival – % (SD) 57.5 (9.4) 71.0 (3.6) 0.188
Table 7: Comparison of patient characteristics for L1CAM positive and negative tumours in both the leiden and the 
TMA cohort
Characteristic L1CAM positive L1CAM negative p-value
n=60 (17%) n=288 (83%)
Follow up – mo (SD) 48.2 (47.7) 59.0 (46.9) 0.108
Age at diagnosis – yr (SD) 72.8 (13.0) 70.7 (13.3) 0.258
FIGO stage – n (%) 0.124
 stage 1 9 (15) 69 (24)
 stage 2 19 (32) 111 (39)
 stage 3 23 (38) 73 (25)
 stage 4 9 (15) 35 (12)
Lymph node metastases – n (%) 29 (48) 102 (35) 0.048*
 Extracapsular growth 15 (25) 42 (15) 0.101
(Continued )
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Although three cores from different locations in the 
tumour were included for each patient, chances still are 
that L1CAM positive areas of the tumour were missed 
when taking these tissue cores. While the percentage of 
L1CAM positive samples was comparable between the 
study and the TMA cohort (16 and 18%), patients might 
have been allocated to the L1CAM negative group, thus 
diluting the effect L1CAM expression has on prognosis. 
The detected differences in survival are therefore on the 
safe side and might in fact be even more significant if 
full slides would have been available for both cohorts 
in this study.
In summary, we have shown for the first time that 
L1CAM is expressed in 17% of the VSCC’s and that 
it is an independent prognostic factor for both overall 
and disease specific survival. Therefore L1CAM proves 
to have potential as a reliable biomarker that can be 
used to discriminate high risk from low risk vulvar 
cancer patients. We have studied and validated this 
prognostic significance in a large cohort of a relatively 
rare cancer type. Our results implicate that, unlike in 
other cancers, p53 and Wnt-signalling do not appear to 
play a dominant role in the (up)regulation of L1CAM. 
More likely, our data point towards a link between EMT 
and L1CAM expression in VSCC. We can conclude that 
L1CAM expression represents a promising prognostic 
biomarker in vulvar cancer. In addition, the potential 
to use L1CAM as a target for therapy based on our 
vulvar cancer cell invasion assays, warrants further 
investigation.
Characteristic L1CAM positive L1CAM negative p-value
n=60 (17%) n=288 (83%)
Tumor size – mm (SD) 36.7 (21.6) 32.1 (18.8) 0.092
Infiltration depth – mm (IQR) 7.0 (4.4 - 11.0) 6.5 (3.5 - 10.0) 0.478
Positive resection margins – n (%) 11 (18.3) 31 (10.8) 0.122
Disease status – n (%)
 Complete remission 31 (52) 203 (71) 0.006*
 Local recurrence 13 (2) 58 (20)
 Regional recurrence 2 (3) 18 (6)
 Distant recurrence 4 (7) 10 (4)
 Died 40 (67) 136 (47) 0.007*
 Disease specific death 19 (32) 56 (19) 0.023*
5-yr Overall survival – % (SD) 46.1 (7.2) 63.6 (3.0) 0.014*
5-yr Disease specific survival – % (SD) 63.8 (7.4) 80.0 (2.5) 0.018*
5-yr Disease free survival – % (SD) 57.5 (9.4) 71.0 (3.6) 0.188
Table 8: Multivariate cox regression analysis for both the leiden and the TMA cohort (n=348)
Disease specific survival
Variable HR 95% CI
Lymph node metastasis 6.1 3.35 - 11.10
Tumour size (mm) 1.02 1.01 - 1.03
L1CAM staining 1.70 0.97 - 2.97
Overall survival
variable HR 95% CI
Lymph node metastasis 2.13 1.54 - 2.93
Tumour size (mm) 1.02 1.02 - 1.03
L1CAM staining 1.58 1.08 - 2.32
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MATERIALS AND METHODS
Patient selection and sample collection
All patients samples were handled according to the 
medical ethical guidelines described in the Code of Conduct 
for Proper Secondary Use of Human Tissue of the Dutch 
Federation of Biomedical Scientific Societies. (www.federa.
org, an English translation of the Code can be found here: 
http://www.federa.org/sites/default/files/digital_version_
first_part_code _of_conduct_in_uk_2011_12092012.pdf)
Two cohorts of patients from two different 
referral cancer centres were included in this study. The 
first cohort exists of 108 patients with primary vulvar 
squamous cell carcinoma who were surgically treated at 
the Leiden University Medical Center between 2000 and 
2009. Of these patients, 5 tissue blocks did not contain 
sufficient tumour tissue anymore and were excluded, 
therefore resulting in a cohort of 103 samples. Patients 
were also excluded if they had received chemotherapy or 
radiotherapy in the pelvic area prior to the operation, or 
if they had received systemic immunosuppressive therapy 
(n=9). Patients who underwent excision biopsies without 
further surgery were excluded, because biopsies do not 
contain enough tumour material (n=11). Clinical and 
follow-up data were retrospectively retrieved from patient 
medical records and the institutional cancer registration 
database. Follow up ended in December 2012.
The second cohort consists of 298 patients with 
primary vulvar squamous cell carcinoma who were 
surgically treated at the University Medical Center 
Groningen between 1984 and 2001. Since 1984, 
clinicopathological and follow-up data of all patients 
referred to the Department of Gynecologic Oncology of 
the University Medical Center Groningen, the Netherlands 
are prospectively collected during standard treatment and 
follow-up. All consecutive vulvar squamous cell cancer 
patients with T1-2 tumors were selected. Twenty-five 
patients were excluded because they did not undergo 
inuinofemoral lymphadenectomy, which was a selection 
criterium in the original study [30]. In 18 cases this was 
because of general bad health, in the other 7 cases because 
Figure 3: Spheroid invasion assay. A. Spindle shaped cells highly express L1CAM, while L1CAM expression on cobble shaped cells 
is very low. B. Spindle and cobble cells form spheroids equally well and invade when embedded in a collagen matrix (C. and D.). Note that 
the invasion of the non-L1CAM expressing cobble shaped cells (C) is hardly affected by L1CAM neutralising antibodies, while spindle cell 
invasion can be strongly inhibited by the L1CAM neutralising antibodies (D)
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of FIGO stage 1A disease. With the tissue samples of 
these patients, a tissue micro array (TMA) was built as 
previously described [30]. Therefore, this cohort will be 
referred to as the ‘TMA cohort’. Patients were excluded 
when they had been treated with preoperative radiotherapy. 
Fiftythree patients were removed from analysis because 
too many cores were missing from the TMA, resulting in 
a cohort of 245 patients in total.
Tumour staging for both cohorts was performed 
according to the FIGO system; the 1995 staging instead 
of the revised 2009 staging was used because of the 
retrospective design of the study [31, 32]. In the multivariate 
survival analysis, we corrected for lymph node metastasis 
and tumour size instead of FIGO stage, because these 
factors are not subject to revisions of staging systems over 
time. These cohorts have been described before [29, 30, 33].
Immunohistochemistry
Formalin fixed, paraffin embedded (FFPE) 
tissue blocks were collected for all included patients. 
4μm sections were cut and sections were stained with 
haematoxylin and eosin to select representative tumour 
containing tissue blocks and areas.
The selected sections were stained using anti 
L1CAM antibody clone 14.1, 1:500 (Covance, Princeton, 
NJ, USA) and counterstained with haematoxylin as 
described before [34]. Stained sections were analysed by 
one PhD-candidate and one gynaecopathologist (MDT 
and TB) separately, blinded for patient characteristics 
and outcome data. L1CAM expression was marked 
“positive” if 5% or more of the tumour cells stained 
moderate or strong for L1CAM. All other staining patterns 
were grouped “L1CAM negative”, which included 1) 
completely negative tumours with positive internal 
control, 2) tumours with scattered positive tumour cells 
(<5%) or 3) very weak stained tumours (intensity was 
compared with internal control).
L1CAM staining of nerve axons was used as an 
internal positive control. A consensus was reached for all 
samples.
The Leiden cohort was also stained for β-catenin 
antibody clone 14 1:800, e-cadherin C20820 1:100 (both 
BD Biosciences, Franklin Lakes, NJ, USA) and vimentin 
V9-2B 1:50 (Department of Pathology, Leiden University 
Medical Center, Leiden, the Netherlands) according to the 
manufacturers protocol.
The TMA cohort consisted of 4 Tissue Micro Arrays 
(TMA) with tumour samples of 298 squamous cell vulvar 
cancer patients [30]. For the TMA cohort, 4μm sections of 
the TMA were cut. Samples on the TMA were scored for 
each tissue core separately, later combining the results from 
the three cores per patient. A patient with at least one core 
with moderate to strong L1CAM expression was scored 
positive for L1CAM, and negative for L1CAM if at least 
two cores were present and all negative. If two or more 
cores were missing or missing for more than 50%, and the 
remaining core was not scored as positive, the patient was 
marked as missing and removed from further analysis.
Tumour cell isolation and spheroid invasion 
assay
From fresh residual tumour tissue (81 year old 
patient, FIGO stage IVa) collected after diagnostic 
use, tumour cells were isolated. Keratin staining of the 
tumour showed both solid and spindle shaped tumour 
cells (Supplementary Figure S1). The tumour was tested 
negative for HPV as described before [29]. Cells were 
harvested after overnight incubation at room temperature 
in 5 ml DMEM (Invitrogen, United Kingdom) containing 
1 mg/ml collagenase and 1 mg/ml dispase. Next day, cells 
were washed and subsequently incubated in RPMI 1640 
containing 10% Fetal Calf Serum (F7524, Sigma-Aldrich, 
USA) 50 U penicillin per ml and 50 μg streptomycin per ml 
(G1397, Sigma-Aldrich, USA. During cell culture cobble 
shaped and spindle shaped tumour cells were identified and 
were separated. Both cell types were cultured further until 
pure populations were obtained. Supplementary Figure S2 
show the morphologic features of the cells. To characterise 
the cells TP53 Sanger sequencing was performed, showing 
a TP53 R248Q mutation identical to the original tumour 
both in the spindle shaped and the cobble shaped cell 
population, reaffirming the epithelial origin of both cell 
types. L1CAM expression on both cell types was evaluated 
by western blot analysis as described before [35] using 
mouse anti- L1CAM antibodies (clone L1-9.3/2a, 2.3 μg/
ml in TBST) and chemoluminescent detection.
The spheroid invasion assay was performed as 
described before [36]. In short, spindle and cobble VSSCs 
were grown to spheroids (500 cells per spheroid) by plating 
them on agarose-coated 96 well plates. After 48h spheroids 
were harvested and embedded in a collagen type-I matrix 
in the presence of 40 μg/ml isotype control or L1CAM 
neutralising antibodies (clone L1-9.3), both kindly provided 
by Prof. Dr. Altevogt [37]. Invasion of the cells into the 
collagen matrix was analysed by microscopy and pictures 
were taken at 1 day after embedding at 10x magnification 
(Olympus microscope). At least 10 spheroids per conditions 
were analysed and the experiment was repeated two times.
HPV and mutation analysis
Mutation analysis and HPV typing were performed 
on the study cohort of 103 patients. The pancytokeratin-
stained slides were used to select an area consisting of 
at least 70% tumour cells. Three 0.6-mm diameter tissue 
cores of variable length were taken from the selected area 
in the FFPE blocks. DNA isolation was performed in an 
automated fashion as described previously using the Tissue 
Preparation System (Siemens Healthcare Diagnostics, 
Malvern, Pennsylvania, USA) [38]. DNA quality was tested 
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by multiplex quality PCR that amplified 150-, 255-, 343-, 
and 511-base pair products that were visualized using 2% 
agarose gel electrophoresis and scored for quality (scale, 
0–4) (primer sequences available upon request).
The INNO-LiPA HPV Genotyping Extra Amp kit 
for in vitro diagnostic use (Innogenetics, Gent, Belgium), 
a highly sensitive hybridization assay, was used for HPV 
typing as described previously [39]. This assay can detect 
oncogenic and common HPV types.
For analysis of somatic mutations in the TP53 
gene, DNA sequencing was performed for exons 5–8 as 
described before [33]. Mutation genotyping of CTNNB1 
was performed using the GynCarta 2.0 panel [40], which 
covers 88% of the currently known CTNNB1 mutations.
Statistical analysis
Statistical analyses were conducted using the 
Predictive Analytics Software package (version 17, 
IBM-SPSS Statistics, Armonk, New York, USA). The 
independent t-test was used to compare baseline variables 
and Fisher’s exact test to analyse categorical and normally 
distributed numerical data. The Shapiro–Wilk test was used 
to test for normality, and for data with a skewed distribution, 
the Mann–Whitney U test was used. Kaplan–Meier, the log-
rank test, and Cox proportional hazard regression analysis 
were performed to analyse differences in survival between 
groups of patients with and without L1CAM expression. A 
P value of .05 was considered significant, corresponding 
to 95% confidence intervals (CIs). All tests were two-
tailed. Results for normally distributed numerical data are 
presented as the mean with standard deviation (SD), and 
results for skewed numerical data are presented as the 
median with interquartile range (IQR).
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